Company Research Report: Mirvie, Inc.

1. Company Overview

Name

• Mirvie, Inc.

Mission of the Company

• Mirvie is dedicated to shaping the future of pregnancy health by providing women and their doctors with an early detection window to intervene before unexpected pregnancy complications become a crisis.

Foundation and Founders

• No information is available.

Key People in the Company

• Maneesh Jain - Chief Executive Officer & Co-Founder

• Stephen Quake - Scientific Advisory Board Chair & Co-Founder

• Michal Elovitz, M.D. - Senior Medical Advisor

• Hong Frank - Head of Software Engineering

• Carrie Haverty - Head of Product Management

• Naomi Kelman - Board Member

• Karen Kirk - Vice President of Finance & Administration

• Stanley Lapidus - Board Chair

• Manfred Lee - Chief Operating Officer

• Alison Moe - Head of Clinical Operations

• Eugeni Namsaraev - Senior Vice President of Research & Development

• Morten Rasmussen - Head of Research

Headquarters

• 651 Gateway Boulevard, Suite 1200, South San Francisco, California 94080

Number of Employees

• No information is available.

Revenue

• No information is available.

Company Recognition

• Mirvie is known for its RNA-based platform that predicts pregnancy complications such as preeclampsia and preterm birth months in advance.

2. Products

The Mirvie RNA Platform

• Description: A platform that predicts pregnancy complications using a simple blood test by analyzing tens of thousands of RNA messages from the mother, baby, and placenta, combined with machine learning.

• Key Features:

• Early Prediction: Can predict complications months before symptoms appear.

• Accuracy: Demonstrates 75% sensitivity in predicting preeclampsia.

• Non-invasive: Utilizes non-invasive blood tests for proactive diagnosis.

3. Recent Developments

New Partnerships and Funding

• In May 2022, Mirvie raised $60 million in Series B funding led by Decheng Capital with participation from BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield. Olympic runner Allyson Felix also invested in this round.

Recent Research and Publications

• Mirvie completed enrollment for its 10,000 person landmark research study on pregnancy complications in November 2023, seeking insights into the underlying biology of pregnancy.

• Ongoing clinical research validating RNA profiles for predictive capabilities regarding preeclampsia and other pregnancy complications.

Innovation and Recognition

• In 2022, published studies in reputed journals such as Nature, and AJOG demonstrated the platform's capabilities to predict pregnancy complications months ahead.

• Mirvie became the first RNA-based pregnancy health-focused company to receive CLIA certification for performing high-complexity clinical testing.

Campaigns and Awareness

• Launched the "Preeclampsia Prevention is Possible" campaign in May 2024, focusing on early detection and prevention strategies for preeclampsia.

Technological Advancements

• Received FDA Breakthrough Device Designation for the platform designed to indicate risk of preeclampsia months before symptoms occur.

• Continuous improvement and validation of the platform’s predictive accuracy through ongoing research.

With Mirvie's innovative approach to prenatal care, they aim to bridge the gap in predicting and preventing adverse pregnancy outcomes, thereby promising a safer and more informed pregnancy journey. This positions Mirvie as a transformational leader in the prenatal health space.